Dissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan
- PMID: 39655086
- PMCID: PMC11626833
- DOI: 10.1016/j.jctube.2024.100497
Dissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan
Abstract
Objectives: To investigate regional variations in pyrazinamide (PZA) prescribing across Japan's 47 prefectures and associated influential factors.
Methods: This study utilized the Standardized Claim Ratio (SCR) for PZA from Japan's National Database of Health Insurance Claims in 2018. Pearson's correlation coefficients assessed relationships between SCR and tuberculosis (TB) incidence, patient characteristics (age, liver disease), and healthcare resources (specialists, TB beds). Multiple regression analysis identified independent predictors of SCR.
Results: Median SCR for PZA was 90.0 (range 40.2-187.1), with a 3-fold difference between top and bottom prefectures. In univariate analysis, SCR correlated positively with TB incidence (r = 0.42), respiratory/infectious disease/TB specialists, and negatively with elderly TB patients (r = -0.33) and liver disease per TB case. Multiple regression revealed higher SCR associated with higher TB incidence (β = 0.44, p < 0.001), lower elderly patients (β = -0.33, p = 0.005), and more respiratory specialists (β = 0.41, p < 0.001).
Conclusions: Regional PZA prescription patterns are multifaceted, significantly influenced by TB prevalence, elderly patient ratios, and the availability of respiratory specialists. To enhance PZA prescribing conformity and TB management, fostering respiratory expertise across Japan is imperative.
Keywords: Elderly patients; Prescribing patterns; Pyrazinamide; Regional variation; Respiratory specialists; Tuberculosis.
© 2024 The Author(s).
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
-
- Furin J., Cox H., Pai M. Tuberculosis. Lancet. 2019;393(10181):1642–1656. - PubMed
-
- World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
-
- Law S., Piatek A.S., Vincent C., Oxlade O., Menzies D. Emergence of drug resistance in patients with tuberculosis cared for by the Indian health-care system: a dynamic modelling study. Lancet Public Health. 2017;2(1):e47–e55. - PubMed
-
- Mehra M., Cossrow N., Kambili C., Underwood R., Makkar R., Potluri R. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis. 2013;17(9):1186–1194. - PubMed
-
- Trauer J.M., Denholm J.T., McBryde E.S. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the Asia-pacific. J Theor Biol. 2014;358:74–84. - PubMed
LinkOut - more resources
Full Text Sources
